- Home
- MODD vs NRSN Comparison
MODD vs NRSN Comparison
Compare MODD & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | NRSN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.5M | 25.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MODD | NRSN |
|---|---|---|
| Price | $4.59 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 39.1K | ★ 140.2K |
| Earning Date | 02-17-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.63 |
| 52 Week High | $6.16 | $2.19 |
Technical Indicators
Market Signals| Indicator | MODD | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 47.47 |
| Support Level | $4.31 | $0.68 |
| Resistance Level | $5.80 | $0.86 |
| Average True Range (ATR) | 0.78 | 0.07 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 33.78 | 37.82 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.